At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Intravenous infusion of transduced cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Gene Therapy Protocol for Adenosine Deaminase Deficiency
Great Ormond Street Hospital for Children NHS Foundation Trust·interventional·Posted Jan 19, 2011·Updated Sep 14, 2015
In Brief
A Phase 2 clinical trial evaluating Intravenous infusion of transduced cells for Adenosine Deaminase Deficiency. Completed, enrolled 8 participants across 1 site.
Detailed Summary
Adenosine deaminase deficiency is an inherited disorder that results in severe abnormalities of the immune system and leaves children unable to fight infection. This trial aims to treat adenosine deaminase deficiency patients using gene therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenosine Deaminase Deficiency
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2003
First PostedJan 2011
Primary CompletionNov 2013
TodayJul 2026
First PostedJan 19, 2011
Enrollment StartOct 1, 2003
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10.1 yearsPosted 15.5 years ago
Interventions
Intravenous infusion of transduced cellsbiological
Intravenous infusion of transduced cells